bims-engexo Biomed News
on Engineered exosomes
Issue of 2026–11–01
eighteen papers selected by
Ravindran Jaganathan, Universiti Kuala Lumpur



  1. Int J Nanomedicine. 2026 ;21 633252
       Background: Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with poor prognosis due to rapid progression and resistance to conventional therapies. Integrin αvβ3 is overexpressed in ATC, making it a promising target. Torin2, a potent mTOR inhibitor, shows antitumor activity but suffers from poor solubility, short half-life, and systemic toxicity. Exosomes offer a natural delivery platform but lack intrinsic tumor tropism. This study aimed to develop iRGD-modified engineered exosomes for targeted delivery of Torin2 to ATC cells.
    Methods: iRGD-modified exosomes (iRGD-Exos) were generated by transducing HEK-293T cells with a lentiviral vector (EGFP-C1-iRGD-Lamp2b) encoding a fusion protein of enhanced green fluorescent protein (EGFP) and iRGD peptide fused to the N-terminus of lysosomal-associated membrane protein 2b (Lamp2b), a transmembrane protein naturally enriched on exosome surfaces. Torin2 was loaded into iRGD-Exos via electroporation (Torin2@iRGD-Exos). The nanoparticles were characterized for size, morphology, loading efficiency, and stability. Cellular uptake was evaluated in ATC cell lines using flow cytometry and confocal microscopy. In vitro cytotoxicity was assessed by live/dead staining. In vivo antitumor efficacy and biosafety were examined in BHT101 xenograft-bearing nude mice.
    Results: iRGD-Exos and Torin2@iRGD-Exos exhibited spherical morphology, appropriate size, and a loading efficiency of 23.68%. iRGD modification significantly enhanced exosome uptake by ATC cells compared to unmodified exosomes. Torin2@iRGD-Exos showed superior in vitro cytotoxicity relative to free Torin2 or Torin2@blank-Exos. In vivo, Torin2@iRGD-Exos markedly suppressed tumor growth without causing significant body weight loss or organ toxicity compared to free Torin2.
    Conclusion: The iRGD-modified exosomal delivery system (Torin2@iRGD-Exos) achieves efficient tumor targeting, excellent biocompatibility, and potent antitumor activity against ATC both in vitro and in vivo, offering a promising therapeutic strategy for integrin αvβ3-overexpressing malignancies.
    Keywords:  Torin2; anaplastic thyroid carcinoma; exosome; iRGD peptide; tumor therapy
    DOI:  https://doi.org/10.2147/IJN.S633252
  2. Mater Today Bio. 2026 Dec;41 103758
      Osteoporosis is characterized by dysregulated bone remodeling driven by excessive osteoclast-mediated bone resorption and insufficient osteoblast-mediated bone formation, often exacerbated by chronic inflammation and oxidative stress. Current pharmacological therapies remain limited by suboptimal efficacy and adverse effects, highlighting the need for alternative strategies that restore bone homeostasis. Here, we developed a bone-targeted, multifunctional exosome-based therapeutic platform by engineering M2 macrophage-derived exosomes co-loaded with platinum nanoparticles (Pt NPs) and a miR-196b inhibitor (BT-Exo-Pt-miR-196 inhibitor). The engineered exosomes exhibited preserved structural integrity, favorable biocompatibility, efficient bone-targeting capability, and excellent in vivo biosafety. Pt NPs endowed the system with robust reactive oxygen species (ROS)-scavenging activity, while M2-derived exosomes and miR-196b inhibition synergistically attenuated inflammatory cytokine expression. In vitro, BT-Exo-Pt-miR-196 inhibitor markedly enhanced osteogenic differentiation, extracellular matrix maturation, and mineralization through coordinated upregulation of osteogenic transcription factors and matrix proteins. Concurrently, osteoclastogenesis was significantly suppressed, as evidenced by reduced TRAP-positive multinucleated cells, impaired actin ring formation, and downregulation of NFATc1 and downstream osteoclast-associated markers. In an ovariectomy-induced osteoporosis mouse model, bone-targeted delivery of BT-Exo-Pt-miR-196 inhibitor effectively preserved trabecular bone microarchitecture, enhanced osteogenic activity, reduced osteoclast function, and alleviated bone loss without inducing systemic toxicity. Collectively, this study demonstrates that bone-targeted M2 macrophage-derived exosomes delivering a miR-196b inhibitor represent a promising immunomodulatory and gene-regulatory nanotherapeutic strategy for restoring bone homeostasis and treating osteoporosis.
    Keywords:  Bone-targeted exosomes; M2 macrophage-derived exosomes; Osteoimmunomodulation; Osteoporosis; miR-196b inhibitor
    DOI:  https://doi.org/10.1016/j.mtbio.2026.103758
  3. Regen Ther. 2026 Dec;33 101185
       Introduction: Teriparatide (TPTD) is an established osteoanabolic agent for the treatment of osteoporosis; however, its short circulating half-life necessitates repeated administration, while limited skeletal selectivity may reduce delivery efficiency. To address these limitations, we developed an Asp6-functionalized, bone-targeting exosome system carrying TPTD mRNA (Asp6-Exo@TPTD). An Exo-Motif sequence was incorporated into the TPTD mRNA construct to facilitate hnRNPA2B1-associated enrichment of the transcript in exosomes, while surface modification with the hydroxyapatite-binding peptide Asp6 was used to enhance skeletal affinity. BMSC-derived exosomes may additionally provide intrinsic regenerative signals that complement the osteoanabolic activity of TPTD.
    Methods: Mouse bone marrow mesenchymal stromal cells (BMSCs) were incubated with different exosome formulations to evaluate intracellular TPTD mRNA transfer, TPTD protein production, CRE-dependent reporter activity, and osteogenic differentiation. Free TPTD was included as a pharmacological reference in the functional, osteogenic, and animal efficacy experiments. The bone-binding properties of the engineered exosomes were assessed using hydroxyapatite-containing bone samples and ex vivo bone tissues. In vivo biodistribution was evaluated by fluorescence imaging after intravenous administration. Therapeutic efficacy was investigated in an ovariectomy-induced osteoporosis mouse model by assessing trabecular microarchitecture, histological changes, serum bone-formation markers, and dynamic bone formation. Preliminary tolerability was evaluated by major-organ histology and serum biochemical analyses, including serum calcium and hepatic and renal function indices.
    Results: Asp6-Exo@TPTD increased intracellular TPTD mRNA levels and TPTD secretion in recipient BMSCs and enhanced CRE-dependent luciferase activity, osteogenic gene expression, alkaline phosphatase staining, and extracellular matrix mineralization. Asp6-Exo@TPTD exhibited greater binding to bone tissues than both unloaded Exo and non-targeted Exo@TPTD in vitro and ex vivo. Following systemic administration, bone-associated fluorescence remained detectable for at least 72 h, with greater femoral and tibial fluorescence and lower relative hepatic fluorescence than those observed with unmodified exosomes. In ovariectomized mice, weekly administration of Asp6-Exo@TPTD improved trabecular microarchitecture, increased serum procollagen type I N-terminal propeptide levels, and enhanced the mineral apposition rate. No overt histopathological abnormalities or significant alterations in serum calcium or routine hepatic and renal biochemical indices were detected.
    Conclusions: Asp6-functionalized exosomes carrying TPTD mRNA promoted osteogenic activity, enhanced bone-associated distribution, and attenuated ovariectomy-induced bone loss. These findings support Asp6-Exo@TPTD as a promising exosome-based strategy for bone-targeted TPTD mRNA delivery and osteoporosis treatment.
    Keywords:  Bone targeting; Exosomes; Osteoporosis; Teriparatide; hnRNPA2B1; mRNA delivery
    DOI:  https://doi.org/10.1016/j.reth.2026.101185
  4. Stem Cell Res Ther. 2026 Jul 28. pii: 382. [Epub ahead of print]17(1):
       BACKGROUND: Adipose-derived stem cell exosomes are increasingly recognized as promising cell-free mediators for soft tissue repair because of their favorable biocompatibility, low immunogenicity, and broad paracrine activity. By transferring regulatory RNAs, proteins, lipids, and other bioactive molecules, they participate in key regenerative processes, including angiogenesis, immune modulation, extracellular matrix remodeling, and cellular proliferation. However, native adipose-derived stem cell exosomes still face important translational limitations, including limited targeting specificity, variable cargo composition, rapid clearance, and insufficient retention at injured sites.
    MAIN BODY: Recent advances in exosome engineering provide new opportunities to enhance the regenerative performance of adipose-derived stem cell exosomes. Function-oriented strategies include parental-cell preconditioning, genetic engineering, direct cargo loading, surface modification, and biomaterial-assisted delivery. These approaches can enrich therapeutic cargos, improve lesion-specific targeting, prolong local retention, and enable sustained or microenvironment-responsive release. Current applications are mainly concentrated in wound healing, muscle repair, and adipose tissue regeneration or fat grafting, while tendon-to-bone healing and peripheral nerve repair represent emerging areas with growing preclinical evidence. This review summarizes the biological basis, engineering strategies, application scenarios, and translational challenges of engineered adipose-derived stem cell exosomes in defined soft tissue regenerative settings.
    CONCLUSION: Although engineered adipose-derived stem cell exosomes show encouraging potential for soft tissue regeneration, clinical translation remains at an early stage. Future development should focus on mechanism-guided cargo design, precise targeting, responsive delivery systems, standardized characterization, and clinically scalable production. These advances may support the development of next-generation cell-free therapies for specific soft tissue repair indications.
    Keywords:  Adipose-derived stem cell exosomes; Biomaterial scaffolds; Clinical translation; Engineered exosomes; Functional engineering; Soft tissue regeneration; Targeted delivery
    DOI:  https://doi.org/10.1186/s13287-026-05153-8
  5. J Drug Target. 2026 Oct 29. 1-19
      N-acetylgalactosamine (GalNAc)-modified extracellular vesicles (EVs) derived from hypoxic pancreatic cancer cells and loaded with annexin A2 (ANXA2) small interfering RNA (siRNA) were developed to modulate the immunosuppressive tumour microenvironment (TME). Characterisation confirmed successful surface modification and efficient siRNA loading in EVs with a diameter of approximately 100-120 nm. In vitro, these engineered EVs inhibited pancreatic cancer cell proliferation, migration and invasion and promoted apoptosis. Additional cargo-matched comparison showed that GalNAc-modified hypoxic EVs carrying ANXA2 siRNA produced stronger ANXA2 silencing and more pronounced anti-migratory, anti-invasive and pro-apoptotic effects than unmodified hypoxic EVs carrying the same siRNA. In a xenograft model, treatment suppressed tumour growth and improved survival. Multi-omics and immune analyses suggested suppression of the PI3K/AKT signalling pathway and remodelling of the immunosuppressive TME, as reflected by increased CD8+ T-cell infiltration, reduced tissue-associated immunoreactivity for interleukin-6 (IL-6), interleukin-10 (IL-10), and tumour necrosis factor-alpha (TNF-α), and increased soluble interferon-gamma (IFN-γ), interleukin-2 (IL-2) and GM-CSF levels. These findings indicate that GalNAc-modified hypoxic EVs carrying ANXA2 siRNA can inhibit tumour progression and modulate the TME in pancreatic cancer, supporting their potential as a therapeutic delivery platform.
    Keywords:  ANXA2 small interfering RNA; Glycosylation; extracellular vesicles; hypoxic tumour; immune microenvironment remodelling; pancreatic cancer
    DOI:  https://doi.org/10.1080/1061186X.2026.2730297
  6. Biomater Sci. 2026 Oct 28.
      mRNA has emerged as a star molecule in pharmaceutical development, demonstrating immense potential for the diagnosis and treatment of cancer, neurological disorders, genetic diseases, and infectious diseases. It has played a particularly pivotal role in COVID-19 prevention. However, the clinical translation of mRNA therapeutics is significantly hampered by its inherent instability, low cellular permeability, and poor targeting specificity. Consequently, the development of efficient mRNA delivery systems represents a paramount challenge for its biomedical application. Conventional delivery platforms, as exemplified by lipid nanoparticles (LNPs), offer advantages including mature manufacturing processes and broad clinical adoption. Nevertheless, they still face limitations such as suboptimal delivery efficiency and biosafety concerns requiring further improvement. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, have emerged as highly promising mRNA delivery vectors. This is attributed to their low immunogenicity, favorable biosafety profile, intrinsic homing effect-based targeting capability, and amenability to engineering modifications. This review comprehensively summarizes recent advances in EV-mediated mRNA delivery, detailing strategies for mRNA loading into EVs, approaches for achieving targeted mRNA delivery using EVs, and the therapeutic applications of EV-encapsulated mRNA. The synthesis of this knowledge aims to provide insights to advance the clinical implementation of mRNA-based therapeutics.
    DOI:  https://doi.org/10.1039/d6bm00986g
  7. J Control Release. 2026 Oct 30. pii: S0168-3659(26)00916-8. [Epub ahead of print] 115512
      Extracellular vesicles (EVs) possess favorable biocompatibility and diverse biological functions, making them promising platforms for therapeutic delivery. However, realizing their full delivery potential requires precise engineering of EVs with tailored functionalities. By bridging chemical tools and biological systems, chemical biology provides a versatile toolkit for the modular engineering of EVs. Here, we provide a systematic overview of recent progress in chemical biology-enabled EV engineering, with an emphasis on three main strategies including protein engineering, nucleic acid engineering, and glycoengineering. In this review, we discuss the design principles of representative approaches and assess their practical utility and performance. Particular attention is given to the integration of orthogonal engineering strategies to coordinate multiple delivery functions within a single EV platform. We further discuss emerging opportunities in multi-specific vesicular antibody design and artificial intelligence (AI)-assisted engineering. By linking molecular engineering strategies with specific delivery requirements, this review provides a comprehensive chemical biology-based framework for the rational design of engineered EVs with tailored delivery functions.
    Keywords:  Biomaterials; Chemical biology; Drug delivery; Extracellular vesicles
    DOI:  https://doi.org/10.1016/j.jconrel.2026.115512
  8. J Drug Target. 2026 Oct 28. 1-45
      This study aimed to investigate the protective effects of nano-formulated vitamin E combined with mesenchymal stem cell (MSC)-derived exosomes in bleomycin-induced lung fibrosis. AD-MSCs were isolated, expanded, and characterized by spindle morphology with high CD105/CD73 and low CD34/CD45 expression. Exosomes isolated from these cells displayed typical spherical morphology (131 nm), high CD81/CD63/CD9 expression, and low CD14. Skin fibrosis was induced in rats by subcutaneous administration of bleomycin. Animals subsequently received free vitamin E, nano-formulated vitamin E, or exosomes loaded with nano-formulated vitamin E. The antifibrotic efficacy of these treatments was assessed using biochemical, molecular, histopathological, and immunohistochemical analyses. Vitamin E nanoemulsion (mean of 48 nm, PDI 0.221, zeta -27.6 mV) was successfully loaded into the exosomes (EE 86.3%, LE 19.8%), yielding stable vesicles (137 nm) with excellent cytocompatibility. The formulation markedly attenuated bleomycin-induced fibrotic injury by restoring redox balance, reduction of TNF-α and TGF-β1 and attenuated extracellular matrix remodeling by decreasing collagen I, α-SMA, MMP-2, and TIMP-1. Moreover, inhibition of the NLRP3/caspase-1/GSDMD pathway and IL-1β indicated suppression of pyroptosis. VEGFR2 expression was also reduced, accompanied by marked improvement in histopathological alterations. The combination therapy exerted pronounced anti-fibrotic effects through coordinated antioxidant, anti-inflammatory, anti-pyroptotic, anti-ECM-remodeling, and anti-angiogenic mechanisms.
    Keywords:  Exosomes; Fibrosis; NLRP3; Nanoformulation; Pyroptosis
    DOI:  https://doi.org/10.1080/1061186X.2026.2757169
  9. Int J Nanomedicine. 2026 ;21 642155
      Breast cancer is a common malignancy affecting women. Brain metastasis is a serious late-stage complication associated with high incidence and poor prognosis, particularly in patients with triple-negative and human epidermal growth factor receptor 2 (HER2) -positive breast cancer. Currently, surgery and radiotherapy are the primary treatment options for breast cancer brain metastasis (BCBM). However, the effectiveness of conventional chemotherapy and immunotherapy is limited by the blood-brain barrier (BBB) and the complex tumor microenvironment, and effective therapeutic strategies remain limited. Exosomes are extracellular vesicles with diameters of 30-150 nm that mediate intercellular communication by transporting active molecules such as proteins and nucleic acids. They play crucial roles in tumor development, progression, and metastasis. Preclinical studies have demonstrated that exosomes promote BCBM through various mechanisms, including BBB remodeling to facilitate tumor cell transmigration, initiation of the pre-metastatic microenvironment, and systemic immune escape mediated by exosomal PD-L1. Genetically or chemically engineered exosomes have demonstrated targeting and drug-delivery potential in preclinical models, making them potential candidates for BCBM treatment. This review summarizes the clinical challenges associated with BCBM and the biological characteristics of exosomes and their mechanisms of action in brain metastasis. It also discusses the potential of exosomes as diagnostic markers, therapeutic targets, and drug delivery carriers, providing insights into future research and clinical translation, which remains challenging and requires further validation.
    Keywords:  blood–brain barrier; breast cancer brain metastasis; engineering strategies; exosomes
    DOI:  https://doi.org/10.2147/IJN.S642155
  10. Int J Nanomedicine. 2026 ;21 633788
       Background: Mitochondrial dysfunction is a major contributor to neuronal death following ischemic stroke, promoting excessive reactive oxygen species (ROS) production, inflammation and apoptotic signaling that exacerbate secondary brain injury. Mdivi-1 has demonstrated mitochondrial and neuroprotective potential; however, its clinical translation is hindered by insufficient accumulation in the ischemic brain, higher systemic doses and associated off-target toxicity. This study aimed to develop a neuron-targeting extracellular vesicle (EV)-based delivery system to enhance the targeted delivery of Mdivi-1 to the ischemic brain.
    Methods: EVs were functionalized with rabies virus glycoprotein peptide (RVG29) via bio-orthogonal click chemistry to generate neuron-targeting RVG-EVs. Mdivi-1 was subsequently loaded into RVG-EVs, and the formulation was characterized for particle size, stability, and drug loading efficiency. HT22 cells were cultured in vitro under oxygen-glucose deprivation (OGD) conditions to evaluate RVG-EV-Mdivi-1 therapeutic potential. For in vivo studies, a mouse transient middle cerebral artery occlusion (tMCAO) model was used to examine the biodistribution, infarct volume, neurological outcomes, mitochondrial dysfunction, oxidative stress, and apoptosis-related signaling pathways.
    Results: RVG-EVs demonstrated enhanced neuronal uptake, and under OGD conditions, RVG-EV-Mdivi-1 significantly attenuated mitochondrial fragmentation and ROS accumulation, thereby preserving mitochondrial function and the cellular bioenergetic balance. In tMCAO mice, biodistribution analysis of fluorescently labeled EVs demonstrated enhanced brain accumulation and neuron targeting of RVG functionalized EVs and RVG-EVs-Mdivi-1 compared to naïve EVs. Systemic administration of RVG-EV-Mdivi-1 produced substantial neuroprotective effects at a lower administered Mdivi-1 dose than free Mdivi-1, reducing infarct volume and improving neurological outcomes. Moreover, RVG-EV-Mdivi-1 alleviated ischemic injury and modulated mitochondrial and apoptosis-related pathways, as evidenced by reduced Drp1 and Bax expression and restored Bcl-2 levels.
    Conclusion: This study demonstrates that RVG-functionalized EVs offer a promising strategy for targeted delivery of Mdivi-1, enhancing brain accumulation and neuronal uptake while alleviating mitochondrial oxidative damage and neuronal injury following ischemic stroke. These findings support the potential of RVG-EV-mediated Mdivi-1 delivery as a neuron-targeting and dose-sparing therapeutic strategy for ischemic stroke.
    Keywords:  Drp1; Mdivi-1; drug delivery; engineered extracellular vesicle; ischemic stroke
    DOI:  https://doi.org/10.2147/IJN.S633788
  11. Adv Healthc Mater. 2026 Oct 26. pii: e71896. [Epub ahead of print]
      Developing effective nanomedicines for pulmonary metastasis remains challenging because of systemic clearance and local stromal barriers. Guided by single-cell transcriptomic profiling, we characterized a compartmentalized immunosuppressive network involving PGE2 and provide a biological rationale for coordinated EP2/EP4 antagonism. We therefore engineered an inhalable biomimetic platform (PD-1@E2/4 Exo) comprising PD-1-displaying exosomes co-loaded with EP2 and EP4 antagonists. Compared with intravenous administration, nebulized delivery increased pulmonary exposure of the engineered vesicles. Within the pulmonary tumor setting, surface PD-1 is intended to interfere with PD-1/PD-L1 signaling, while the co-delivered antagonists target the EP2/EP4 immunosuppressive axis. Treatment was associated with macrophage reprogramming, increased oxidative stress, and enhanced ICD-related responses in tumor cells. In the experimental breast-cancer lung-colonization model, the inhaled formulation reduced established pulmonary tumor burden and was accompanied by systemic immune-memory responses. These findings provide a preclinical study for integrating local pulmonary delivery with coordinated metabolic and immune modulation in breast cancer lung disease.
    Keywords:  EP2/EP4 antagonism; PD‐1/PD‐L1 interaction; exosomes; inhalable nanomedicines; pulmonary tumor burden; triple‐negative breast cancer
    DOI:  https://doi.org/10.1002/adhm.71896
  12. Pharmaceutics. 2026 Sep 24. pii: 1215. [Epub ahead of print]18(10):
      Nanomedicine harnesses the unique benefits of nanocarriers to markedly enhance drugs targeting tumors, which is becoming a promising approach to achieve precise and effective antitumor therapy. Extracellular vesicles (EVs), natural nanoscale entities, have garnered extensive attention due to their high biocompatibility and low immunogenicity. However, they often lack the specificity to identify and target lesion sites, leading to side effects when used systemically. Thus, modifying EVs to enhance their targeting ability is crucial. This review comprehensively elucidates the use of natural EVs in tumor treatment and functionalization strategies for EVs, including bioengineering modifications of parent cells, covalent and noncovalent modifications for the EV surface. The particular emphasis is placed on the precision delivery strategies of these functionalized EVs. According to the different delivery endpoints, they can be classified into tumor microenvironment delivery, intracellular delivery into tumor cells, and dual delivery to the tumor microenvironment and the tumor cell. Future perspectives focus on the essential aspects of constructing functionalized EVs and anticipate their evolving role in tumor-targeted therapies. Overall, this review offers a thorough analysis of recent advancements in functionalized EVs for antitumor therapy, providing valuable insights for their future development and precision biomedical applications.
    Keywords:  antitumor therapy; extracellular vesicles; functional modification; precision delivery; targeted recognition
    DOI:  https://doi.org/10.3390/pharmaceutics18101215
  13. Molecules. 2026 Oct 19. pii: 3754. [Epub ahead of print]31(20):
      Plant-derived extracellular vesicles (PDEVs) are being recognized as a capable novel class of natural nanocarriers that have important uses in delivering bioactives and facilitating innovations in functional foods and precision health technologies. PDEVs are lipid-bilayer-enclosed vesicular structures that commonly occur at the nanoscale, although their reported sizes vary depending on the plant source, isolation procedure, and measurement method. They contain diverse biomolecules, including lipids, proteins, microRNAs, and phytochemicals, and have been investigated for their potential roles in interspecies communication and the delivery of bioactive compounds. Compared with some conventional nanocarriers, PDEVs have shown favorable biocompatibility and stability under certain experimental conditions; however, these properties are dependent on the plant source, isolation method, cargo, formulation, and experimental model; therefore, they are uniquely positioned for oral delivery systems. This review presents a complete picture of the process of PDEV biogenesis, the molecular architecture of PDEVs, and their cargo. We evaluate and compare the source materials of PDEVs to determine whether they will influence how effectively the bioactive agent is delivered to its intended target and produce the therapeutic effect. Additionally, we present a review of the advances in technology for the analysis of PDEVs: methods of extraction, purification, and characterization of PDEV; current and future techniques for loading cargo into PDEVs; methods of modifying the surfaces of PDEVs; and methods of developing, producing, and delivering hybrid systems of PDEVs. Finally, a comprehensive review of the use of PDEVs in delivering nutraceuticals, modulating the gut microbiome, delivering probiotic systems, and exhibiting anti-inflammatory, antioxidant, and anti-cancer effects. Even as these positive advancements occur, challenges related to scalability, standardization, and purity remain significant barriers to industrial translation. PDEVs are well-positioned to serve as a sustainable, next-generation nanoplatform at the intersection of nanotechnology, food science, and biomedicine. PDEVs also provide unprecedented opportunities to advance functional foods and precision nutrition.
    Keywords:  bioactive delivery; cross-kingdom communication; functional foods; gut microbiota; nanobiotechnology; nanocarriers; plant-derived extracellular vesicles (PDEVs); precision nutrition
    DOI:  https://doi.org/10.3390/molecules31203754
  14. Adv Healthc Mater. 2026 Oct 26. pii: e71909. [Epub ahead of print]
      Lipid nanoparticle (LNP)-enabled genetic medicines are reshaping cancer therapy yet remain constrained by liver-biased tropism, dose-limiting toxicities, and limited efficacy in refractory solid tumors such as pancreatic ductal adenocarcinoma (PDAC). Here, exosome-inspired proteolipid nanoparticles (Em-pLNPs) are developed to embed three exosomal membrane proteins within an ionizable lipid matrix to support safe, extrahepatic delivery of combinatorial gene-chemo payloads. Em-pLNPs are generated by one-step microfluidic mixing to incorporate the tetraspanins CD63 and CD81 and the "don't-eat-me" marker CD47 into the lipid shell, co-encapsulate diverse nucleic acid and small-molecule cargos, and enable modular CD44-targeted surface functionalization. Following systemic administration in orthotopic PDAC models, Em-pLNPs exhibit prolonged circulation, preferential extrahepatic tumor accumulation, deep penetration of desmoplastic stroma, and efficient cytosolic delivery, while markedly improving tissue tolerability relative to ligand-decorated clinical LNP benchmarks. Formulated with an RNAi-chemo cocktail (siKRAS, siIL-6, and gemcitabine), Em-pLNPs permit repeated intravenous dosing that drives robust, synergistic tumor regression and mitigates chemoresistance. By coupling exosome-like immune evasion and tissue tropism with the manufacturability and high gene-loading capacity of LNPs, Em-pLNPs define a translational proteolipid platform for safe extrahepatic gene therapy against refractory solid tumors.
    Keywords:  exosome mimetics; extrahepatic delivery; gene therapies; lipid nanoparticles; pancreatic ductal adenocarcinoma
    DOI:  https://doi.org/10.1002/adhm.71909
  15. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2026 Oct 25. 43(5): 1068-1074
      To address the clinical challenges of limited therapeutic efficacy and pronounced toxicity associated with conventional intravesical chemotherapy due to the bladder mucosal barrier, this study constructs an extracellular vesicles (EVs)-based drug delivery system loaded with pirarubicin (THP), designated as EVs@THP. EVs derived from MB49 bladder tumor cells were extracted by ultracentrifugation and loaded with THP. Structural characterization confirmed that EVs@THP maintained stable vesicle structure. In vitro cell experiments showed that EVs@THP could be efficiently internalized by bladder cancer cells and presented stronger tumor killing ability compared with free THP. In vivo experiments using orthotopic bladder cancer mouse models further proved that EVs@THP possessed better tissue penetration and intravesical retention after perfusion, with significantly superior antitumor efficacy to free THP. MB49 cell-derived EVs are promising delivery carriers for THP. The EVs@THP system with good biocompatibility and targeting ability can effectively improve the outcome of bladder cancer intravesical chemotherapy, providing experimental evidence for the development and transformation of novel intravesical therapeutic regimens.
    Keywords:  Bladder cancer; Extracellular vesicles; Intravesical perfusion; Pirarubicin
    DOI:  https://doi.org/10.7507/1001-5515.202605010
  16. Inflammation. 2026 Jul 29. pii: 206. [Epub ahead of print]49(1):
      Sepsis is a serious disease associated with macrophage polarization and endothelial permeability. The DAG/PKC/ROS pathway is crucial for sepsis development, macrophage polarization and endothelial permeability. As CD4+T cell-derived exosomes can modulate the DAG/PKC/ROS pathway, we aimed to investigate the role and mechanism of exosomes from DGKK-knockdown CD4+T cells in sepsis. RAW264.7 cells were exposed to lipopolysaccharide and interferon-gamma (L/I) to promote M1 polarization and then co-cultured with exosomes. The macrophages were co-cultured with lipopolysaccharide-stimulated PMVECs. Additionally, phorbol 12-myristate 13-acetate (PMA), a PKC agonist, was used to treat macrophages. Furthermore, sepsis mouse models were established via cecal ligation and puncture (CLP) surgery. In vitro, lipopolysaccharide increased DGKK expression in CD4⁺T cells and CD4⁺T cell-derived exosomes. L/I-induced M1 macrophage polarization and DAG/PKC/ROS pathway activation were amplified by lipopolysaccharide-stimulated CD4⁺T cell exosomes. However, exosomes from DGKK-knockdown CD4⁺T cells counteracted these effects. Furthermore, treatment with these exosomes improved PMVEC viability, decreased apoptosis, alleviated inflammation, and decreased permeability. In vivo, CLP-induced inflammation, organ (lung/liver/kidney) injury, M1 macrophage polarization, DAG/PKC/ROS pathway activation, and lung permeability were further aggravated by LPS-stimulated CD4⁺T cell exosomes. However, exosomes from DGKK-knockdown CD4⁺T cells counteracted these deteriorations, while macrophage depletion abolished the protective effects of DGKK-knockdown CD4⁺T cell-derived exosomes in sepsis. Importantly, the effects of exosomes from DGKK-knockdown CD4⁺T cells on M1 macrophage polarization and endothelial permeability were reversed by PMA. In conclusion, exosomes from DGKK-knockdown CD4+T cells mitigated sepsis by suppressing the DAG/PKC/ROS pathway-mediated M1 macrophage polarization and reducing endothelial permeability, suggesting DGKK as a promising therapeutic target for sepsis.
    Keywords:  DAG/PKC/ROS pathway; DGKK; Endothelial permeability; Exosome; M1 macrophage polarization; Sepsis
    DOI:  https://doi.org/10.1007/s10753-026-02566-8
  17. Nanomedicine (Lond). 2026 Oct;21(20): 2829-2843
       AIMS: Tobacco smoking independently contributes to osteoporosis. Cigarette smoke-derived reactive oxygen species (ROS) and transition metals promote iron accumulation and impair mitophagy in bone marrow mesenchymal stem cells (BMSCs), causing mitochondrial dysfunction, reduced osteogenic differentiation, and iron-induced osteoporosis. The molecular pathways linking smoke exposure to impaired bone formation remain incompletely understood.
    MATERIALS AND METHODS: We established a cigarette smoke extract (CSE)-induced bone-loss model in female C57BL/6J mice (n = 8/group) and performed femoral transcriptomic profiling. Bone-targeting extracellular vesicles from stem cells from human exfoliated deciduous teeth (SHED-EVs) were loaded with siRNA against mitochondrial ferritin (FtMt; siFtMt) to generate BT-siFtMt@SHED-EVs. The nanoplatform was characterized and tested in vitro and in vivo using micro-CT, JC-1, Alkaline Phosphatase/alizarin red S, immunostaining, RT-qPCR, Western blotting, and in silico docking (ZDOCK/RDOCK).
    RESULTS: CSE upregulated FtMt while suppressing mitophagy and osteogenic differentiation. BT-siFtMt@SHED-EVs restored mitochondrial membrane potential, reinstated mitophagic flux, and rescued BMSC osteogenesis. Systemically administered BT-siFtMt@SHED-EVs restored trabecular microarchitecture and bone mineral density and elevated osteogenic markers in CSE-exposed mice; these benefits were abolished by the mitophagy inhibitor Mdivi-1.
    CONCLUSIONS: Targeted FtMt knockdown via bone-homing SHED-EVs reinstates mitochondrial quality control and ameliorates smoke-related bone loss, offering a precision mitochondrial medicine approach to osteoporosis.
    Keywords:  Osteoporosis; bone regeneration; bone-targeting delivery; cigarette smoke extract; extracellular vesicles; mitochondrial ferritin; mitophagy; siRNA
    DOI:  https://doi.org/10.1080/17435889.2026.2748269
  18. ScientificWorldJournal. 2026 ;pii: e5346779. [Epub ahead of print]2026(1):
      Osteosarcoma (OS) is a malignant bone tumour that mostly affects adolescents. Although conventional treatment approaches improved disease prognosis significantly, high metastasis rate and recurrence impose a substantial disease burden on patients. Therefore, innovation of targeted therapy is of pressing importance towards better disease prognosis. Several in vitro studies using microRNA delivered via mesenchymal stem cell-derived extracellular vesicles presented significant results in reducing OS metastatic properties. Henceforth, the objective of this study, which is to compile and analyse data from relevant studies, subsequently provides a comprehensive and evidence-based summary that validates the tumour-suppressive role of miRNA-loaded MSC-derived EVs targeting OS metastasis. Studies were systematically selected from three databases: PubMed, Web of Science and Scopus, according to the PRISMA criteria and flowchart. Experimental data regarding proliferation, apoptosis, migration and invasion were extracted using WebPlotDigitizer and analysed using the Comprehensive Meta-Analysis (CMA) software. A systematic search from databases identified 33 studies, with four studies fulfilling the inclusion and exclusion criteria after final screening process. The pooled meta-analysis demonstrated that miRNA-loaded MSC-derived EVs were associated with a significant decrease in proliferation, migration and invasion rates of the OS cells, with a significant increase in apoptosis rate. Moreover, low to moderate heterogeneity was observed across selected studies. This review confirms that miRNA-loaded MSC-derived EVs significantly suppressed OS metastasis by inhibiting proliferation, migration and invasion while promoting apoptosis. However, clinical translation is currently limited by the lack of standardised protocols necessary for large-scale trials to validate EV-based therapies as a potential therapeutic approach in the future.
    Keywords:  exosomes; extracellular vesicles; mesenchymal stem cells; miRNA; osteosarcoma metastasis
    DOI:  https://doi.org/10.1155/tswj/5346779